Dr. Cohen on Immunotherapy in Head and Neck Squamous Cell Carcinoma

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy in head and neck squamous cell carcinoma.

Immunotherapy is currently used as standard of care for patients who have either recurred after curative intent therapy within 6 months of completion, or in patients who have had progressed on first-line platinum-containing therapy.